Evaluation of the Enzymatic Activity of Soluble CD13/APN and CD26/DPP4 in Serum and Urine Samples of Mice with Experimental Autoimmune Encephalomyelitis
Novelty in Biomedicine,
Vol. 9 No. 4 (2021),
12 November 2021
,
Page 178-184
https://doi.org/10.22037/nbm.v9i4.34291
Abstract
Background: Dipeptidyl Peptidase IV (DPP4/CD26) and Amino Peptidase N (APN/CD13) have essential roles in inflammatory diseases. The current study aimed to determine changes in APN and DPP4 enzyme activity in the serum and urine of mice with experimental autoimmune encephalomyelitis (EAE).Materials and Methods: In the present study, female C57BL/6 mice were studied in two groups (control and EAE). Twenty-sevendays after induction, the enzymatic activity of APN and DPP4 in urine and serum samples was measured using a spectrophotometric assay.
Results: The enzyme activity of DPP4 was higher in serum and urine of EAE mice than in the control group (mean in serum: 1.04 ± 0.13 pmol/mL and 0.80 ± 0.12 pmol/mL, respectively, P=0.015; mean in urine: 0.26 ± 0.04 pmol/mL and 0.19 ± 0.04 pmol/mL, respectively, P=0.015). However, the enzymatic activity of APN in serum and urine of mice with EAE when compared to the control group had no significant difference (mean in serum: 9.20 ± 1.15 unit/mL and 10.25 ± 1.21 unit/mL, respectively, P=0.132, mean in urine: 0.23 ± 0.27 unit/mL and 0.15 ± 0.05 unit/mL, respectively, P=0.310).
Conclusion: The increased DPP4 activity along with normal APN activity in urine and serum samples can be used as an indicator to detect or follow up on the course of MS disease. Confirmation of this finding needs further investigation.
- Aminopeptidase N, CD13, CD26, Dipeptidyl peptidase 4, Experimental autoimmune encephalomyelitis
How to Cite
References
Sahraian MA, Pakdaman H, Harandi AA. Is it time to revise the classification of geographical distribution of multiple Sclerosis? Vol. 11, Iranian journal of neurology. 2012;77–778.
Lassmann H. What drives disease in multiple Sclerosis: Inflammation or neurodegeneration? Vol. 1, Clinical and Experimental Neuroimmunology. 2010;2–11.
Cheng Y, Sun L, Xie Z, Fan X, Cao Q, Han J, et al. Diversity of immune cell types in multiple sclerosis and its animal model: Pathological and therapeutic implications. J Neurosci Res [Internet]. 2017/01/13. 2017;95(10):1973–83.
Constantinescu CS, Kamoun M, Dotti M, Farber RE, Galetta SL, Rostami A. A longitudinal study of the T cell activation marker CD26 in chronic progressive multiple Sclerosis. J Neurol Sci. 1995;130(2):178–82.
Reinhold D, Biton A, Pieper S, Lendeckel U, Faust J, Neubert K, et al. Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation. Int Immunopharmacol. 2006;6(13–14):1935–42.
Gabrilovac J, Breljak D, Čupić B, Ambriović-Ristov A. Regulation of aminopeptidase N (EC 3.4.11.2; APN; CD13) by interferon-γ on the HL-60 cell line. Life Sci. 2005;76(23):2681–97.
Ikeda T, Kumagai E, Iwata S, Yamakawa A. Soluble CD26/Dipeptidyl Peptidase IV Enhances the Transcription of IL-6 and TNF-α in THP-1 Cells and Monocytes. Vol. 8, PLoS ONE. 2013.
Riemann D, Kehlen A, Langner J. CD13 - Not just a marker in leukemia typing. Immunol Today. 1999;20(2):83–8.
Busek P, Malik R, Sedo A. Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. Int J Biochem Cell Biol. 2004;36:408–21.
George SG, Kenny AJ. Studies on the enzymology of purified preparations of brush border from rabbit kidney. Biochem J [Internet]. 1973;134(1):43–57.
Bengsch B, Seigel B, Flecken T, Wolanski J, Blum HE, Thimme R. Human Th17 Cells Express High Levels of Enzymatically Active Dipeptidylpeptidase IV (CD26). J Immunol. 2012;188(11):5438
Ahmed RH, Huri HZ, Al-Hamodi Z, Salem SD, Al-absi B, Muniandy S. Association of DPP4 gene polymorphisms with type 2 diabetes mellitus in Malaysian subjects. PLoS ONE. 2016;11.
Hatano R, Yamada T, Madokoro H, Otsuka H, Komiya E, Itoh T, et al. Development of novel monoclonal antibodies with specific binding affinity for denatured human CD26 in formalin-fixed paraffin-embedded and decalcified specimens. PLoS One. 2019;14(6):0218330.
Hafler DA, Fox DA, Manning ME, Schlossman SF, Reinherz EL, Weiner HL. In Vivo Activated T Lymphocytes in the Peripheral Blood and Cerebrospinal Fluid of Patients with Multiple Sclerosis. N Engl J Med. 1985;312(22):1405–11.
Sellebjerg F, Christiansen M, Jensen J, Frederiksen JL. Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple Sclerosis. European Journal of Neurology. 2000;7:281–9.
Tejera-Alhambra M, Casrouge A, de Andrés C, Ramos-Medina R, Alonso B, Vega J, et al. Low DPP4 expression and activity in multiple sclerosis. Clin Immunol [Internet]. 2014;150(2):170–83.
Krakauer M, Sorensen PS, Sellebjerg F. CD4+ memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple Sclerosis. J Neuroimmunol. 2006;181(1–2):157–64.
Khoury SJ, Guttmann CRG, Orav EJ, Kikinis R, Jolesz FA, Weiner HL. Changes in activated T cells in the blood correlate with disease activity in multiple Sclerosis. Arch Neurol. 2000;57(8):1183–9.
Bradshaw MJ, Bhattacharyya S, Venna N, Cahill JF. Neurologic Manifestations of Systemic Rheumatologic Diseases. Current Clinical Neurology. 2020; 321–42.
Reinhold D, Biton A, Pieper S, Lendeckel U, Faust J, Neubert K, et al. Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation. Int Immunopharmacol. 2006;6(13–14):1935–42.
Reinhold D, Bank U, Täger M, Ansorge S, Wrenger S, Thielitz A, et al. Table of contents 1. 2008;2356–63.
Ayatollahi AM, Haji Molla Hoseini M, Ghanadian SM, Kosari-Nasab M, Mami F, Yazdiniapoure Z, et al. TAMEC: a new analogue of cyclomyrsinol diterpenes decreases anxiety- and depression-like behaviors in a mouse model of multiple Sclerosis. Neurol Res. 2017;39(12):1056–65.
Mami S, Yeganeh F, Farahani E, Anissian A, Haji M, Hoseini M, et al. Chitin Micro Particles Regulate Splenocytes Immune Response in Experimental Autoimmune Encephalomyelitis Contrasting studies are reported on the induction of IL-10 and IFN- γ via chitin microparticles (CMPs) during immune stimulation. Our previous stud. 2018.
Behzadi M, Ahmadzadeh A, Valizadeh M, Haji Molla Hoseini M, Yeganeh F. CD13/aminopeptidase N mRNA expression and enzyme activity in Systemic Lupus Erythematosus. Acta reumatologica portuguesa. 2017;42:162–7.
Yeganeh F, Mousavi SMJ, Hosseinzadeh-Sarband S, Ahmadzadeh A, Bahrami-Motlagh H, Hoseini MHM, et al. Association of CD26/dipeptidyl peptidase IV mRNA level in peripheral blood mononuclear cells with disease activity and bone erosion in rheumatoid arthritis. Clin Rheumatol. 2018;37(12):3183–90.
Beckenkamp A, Willig JB, Santana DB, Nascimento J, Paccez JD, Zerbini LF, et al. Differential expression and enzymatic activity of DPPIV/CD26 affects migration ability of cervical carcinoma cells. PLoS ONE. 2015;10.
Jové M, Portero-Otín M, Naudí A, Ferrer I, Pamplona R. Metabolomics of Human Brain Aging and Age-Related Neurodegenerative Diseases. J Neuropathol Exp Neurol [Internet]. 2014;73(7):640–57.
Schanstra JP, Mischak H. Proteomic urinary biomarker approach in renal disease: from discovery to implementation. Pediatr Nephrol. 2015;30(5):713-25.
An M, Gao Y. Urinary Biomarkers of Brain Diseases. Genomics Proteomics Bioinformatics. 2016;13.
Cho EH, Kim SW. Soluble Dipeptidyl Peptidase-4 Levels Are Associated with Decreased Renal Function in Patients with Type 2 Diabetes Mellitus. Diabetes Metab J. 2018/10/08. 2019;43(1):97–104.
Valencia-Sánchez L, Almendra-Pegueros R, R-Valdez LJD, Esmer-Sánchez D, Medina Ú, Gordillo-Moscoso A. DPP-4 as a Possible Biomarker of Inflammation Before Abdominal Surgery for Chronic Pathology: Our Experience with Elective Cholecystectomy. Medicina (Kaunas). 2019;55(5):148.
Jensen J, Langkilde AR, Fenst C, Nicolaisen MS, Roed HG, Christiansen M, et al. CD4 T cell activation and disease activity at onset of multiple Sclerosis. Journal of Neuroimmunology. 2004;149:202–9.
Bomprezzi R, Ringnér M, Kim S, Bittner ML, Khan J, Chen Y, et al. Gene expression profile in multiple sclerosis patients and healthy controls: Identifying pathways relevant to disease. Hum Mol Genet. 2003;12(17):2191–9.
Pérez I, Varona A, Blanco L, Gil J, Santaolalla F, Zabala A, et al. Increased APN/CD13 and acid aminopeptidase activities in head and neck squamous cell carcinoma. Head Neck. 2009;31(10):1335–40.
Rangel R, Sun Y, Guzman-Rojas L, Ozawa MG, Sun J, Giordano RJ, et al. Impaired angiogenesis in aminopeptidase N-null mice. Proceedings of the National Academy of Sciences of the United States of America. 2007;104:4588–93.
Holler E, Dickinson A. Biomarkers in chronic graft versus host disease. Chronic Graft Versus Host Disease: Interdisciplinary Management. 2009;79–84.
Ziaber J, Baj Z, Paśnik J, Chmielewski H, Tchórzewski H. Increased expression of neutral endopeptidase (NEP) and aminopeptidase N (APN) on peripheral blood mononuclear cells in patients with multiple Sclerosis. Immunol Lett. 2000;71(2):127–9.
Mitic B, Lazarevic G, Vlahovic P, Rajic M, Stefanovic V. Diagnostic value of the aminopeptidase N, N-acetyl-beta-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies. Ren Fail. 2008;30(9):896–903.
- Abstract Viewed: 83 times
- pdf Downloaded: 86 times